Lamotrigine in mood disorders

被引:20
作者
Green, B [1 ]
机构
[1] Univ Liverpool, Dept Psychiat, Liverpool L69 3BX, Merseyside, England
关键词
affective disorder; anticonvulsants; bipolar disorder; depressive disorder; lamotrigine; BIPOLAR-I-DEPRESSION; DOUBLE-BLIND; GABAPENTIN MONOTHERAPY; TERM LAMOTRIGINE; PHARMACOKINETICS; EPILEPSY; STABILIZERS; ANTICONVULSANTS; CARBAMAZEPINE; MECHANISMS;
D O I
10.1185/030079903125001703
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lannotrigine is an anticonvulsant drug with good efficacy and safety in the treatment of epilepsy. There is now substantial evidence that lamotrigine is also useful in treating resistant depression, rapid cycling bipolar affective disorder, depressive episodes in bipolar affective disorder and in the maintenance phase or prophylaxis of bipolar affective disorder. There are possible roles in managing mood changes in borderline personality disorder, reducing chronic pain and treating schizoaffective disorder. The general range of doses found effective in affective disorders is from 50 to 300 mg daily. Clinical use seems to involve a titration of dose upwards over several weeks until the desired effect is obtained. However, further definitive double-blind, randomised controlled trials against gold standard treatments are required. Lamotrigine has a preferable side-effect profile compared to standard agents for bipolar affective disorder such as lithium or carbamazepine. Further research is certainly warranted and, given its tolerability, could point to lamotrigine as the treatment of choice for some affective disorders.
引用
收藏
页码:272 / 277
页数:6
相关论文
共 49 条
[1]   Successful re-introduction of lamotrigine after initial rash [J].
Besag, FMC ;
Ng, GYT ;
Pool, F .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2000, 9 (04) :282-286
[2]   Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy [J].
Biton, V ;
Mirza, W ;
Montouris, G ;
Vuong, A ;
Hammer, AE ;
Barrett, PS .
NEUROLOGY, 2001, 56 (02) :172-177
[3]   Novel treatments for bipolar disorder [J].
Bowden, CL .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (04) :661-671
[4]   A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression [J].
Calabrese, JR ;
Bowden, CL ;
Sachs, GS ;
Ascher, JA ;
Monaghan, E ;
Rudd, GD .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (02) :79-+
[5]  
Calabrese JR, 1999, AM J PSYCHIAT, V156, P1019
[6]   Controlled trials in bipolar I depression: focus on switch rates and efficacy [J].
Calabrese, JR ;
Rapport, DJ ;
Kimmel, SE ;
Shelton, MD .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1999, 9 :S109-S112
[7]   A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder [J].
Calabrese, JR ;
Suppes, T ;
Bowden, CL ;
Sachs, GS ;
Swann, AC ;
McElroy, SL ;
Kusumakar, V ;
Ascher, JA ;
Earl, NL ;
Greene, PL ;
Monaghan, ET .
JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (11) :841-850
[8]  
Chang K D, 2001, Expert Opin Pharmacother, V2, P613, DOI 10.1517/14656566.2.4.613
[9]   Mood stabilizers during breastfeeding: A review [J].
Chaudron, LH ;
Jefferson, JW .
JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (02) :79-90
[10]   The effects of lamotrigine on the pharmacokinetics of lithium [J].
Chen, C ;
Veronese, L ;
Yin, Y .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (03) :193-195